|
SABCS abstract number...link please!
SABCS 2007: ABSTRACT #23: Fulvestrant 500 mg vs 250 mg: first results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer
[
|